Giuseppe
Emeritus
[Source: Antimicrobial Agents and Chemotherapy, full page: (LINK). Abstract, edited.]
In Vitro Activity of Ceftaroline-Avibactam Against Gram-Negative and Gram-Positive Pathogens Isolated from Patients in Canadian Hospitals in 2010?2012: Results from the CANWARD Surveillance Study
James A. Karlowsky 1,2*, Heather J. Adam 1,2, Melanie R. Baxter 2, Philippe R. S. Lagac?-Wiens 1,2, Andrew J. Walkty 1,2,3, Daryl J. Hoban 1,2 and George G. Zhanel 2
Author Affiliations: Diagnostic Services Manitoba,<SUP>1</SUP> Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba,<SUP>2</SUP> and Department of Medicine, Health Sciences Centre,<SUP>3</SUP> Winnipeg, Manitoba, Canada
ABSTRACT
The in vitro activities of ceftaroline-avibactam, ceftaroline and comparative agents were determined for a collection of frequent bacterial pathogens isolated from patients seeking care at 15 Canadian hospitals from January 2010 to December 2012. In total, 9758 isolates were tested using the Clinical and Laboratory Standards Institute (CLSI) broth microdilution method (M07-A9, 2012) with MICs interpreted using CLSI breakpoints (M100-S23, 2013). Ceftaroline-avibactam demonstrated potent activity (MIC<SUB>90</SUB>, ≤0.5 μg/ml) against Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis, Enterobacter cloacae, Enterobacter aerogenes, Serratia marcescens, Morganella morganii, Citrobacter freundii and Haemophilus influenzae; >99% of isolates of E. coli, K. pneumoniae, K. oxytoca, P. mirabilis, M. morganii, C. freundii and H. influenzae were susceptible to ceftaroline-avibactam using CLSI MIC interpretative criteria for ceftaroline. Ceftaroline was less active than ceftaroline-avibactam against all species of Enterobacteriaceae tested with rates of susceptibility ranging from 93.9% (P. mirabilis) to 54.0% (S. marcescens). All isolates of methicillin-susceptible Staphylococcus aureus (MIC<SUB>90</SUB>, 0.25 μg/ml) and 99.6% of methicillin-resistant S. aureus (MIC<SUB>90</SUB>, 1 μg/ml) were susceptible to ceftaroline; the addition of avibactam to ceftaroline did not alter its activity against staphylococci or streptococci. All isolates of Streptococcus pneumoniae (MIC<SUB>90</SUB>, 0.03 μg/ml), Streptococcus pyogenes (MIC<SUB>90</SUB>, ≤0.03 μg/ml), and Streptococcus agalactiae (MIC<SUB>90</SUB>, 0.015 μg/ml) tested were susceptible to ceftaroline. We conclude that combining avibactam with ceftaroline expanded its spectrum of activity to include most isolates of Enterobacteriaceae resistant to third-generation cephalosporins, including extended-spectrum β-lactamase (ESBL)- and AmpC-producing E. coli and ESBL-producing K. pneumoniae, while maintaining potent activity against staphylococci and streptococci.
FOOTNOTES
* Corresponding author. Mailing address: Department of Clinical Microbiology, St. Boniface Hospital, 409 Tach? Avenue, L4025-9, Winnipeg, Manitoba, R2H 2A6, Canada, Phone: (204) 237-2125. Fax: (204) 237-7678. E-mail: jkarlowsky@dsmanitoba.ca.
Copyright ? 2013, American Society for Microbiology. All Rights Reserved.
-
-------
In Vitro Activity of Ceftaroline-Avibactam Against Gram-Negative and Gram-Positive Pathogens Isolated from Patients in Canadian Hospitals in 2010?2012: Results from the CANWARD Surveillance Study
James A. Karlowsky 1,2*, Heather J. Adam 1,2, Melanie R. Baxter 2, Philippe R. S. Lagac?-Wiens 1,2, Andrew J. Walkty 1,2,3, Daryl J. Hoban 1,2 and George G. Zhanel 2
Author Affiliations: Diagnostic Services Manitoba,<SUP>1</SUP> Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba,<SUP>2</SUP> and Department of Medicine, Health Sciences Centre,<SUP>3</SUP> Winnipeg, Manitoba, Canada
ABSTRACT
The in vitro activities of ceftaroline-avibactam, ceftaroline and comparative agents were determined for a collection of frequent bacterial pathogens isolated from patients seeking care at 15 Canadian hospitals from January 2010 to December 2012. In total, 9758 isolates were tested using the Clinical and Laboratory Standards Institute (CLSI) broth microdilution method (M07-A9, 2012) with MICs interpreted using CLSI breakpoints (M100-S23, 2013). Ceftaroline-avibactam demonstrated potent activity (MIC<SUB>90</SUB>, ≤0.5 μg/ml) against Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis, Enterobacter cloacae, Enterobacter aerogenes, Serratia marcescens, Morganella morganii, Citrobacter freundii and Haemophilus influenzae; >99% of isolates of E. coli, K. pneumoniae, K. oxytoca, P. mirabilis, M. morganii, C. freundii and H. influenzae were susceptible to ceftaroline-avibactam using CLSI MIC interpretative criteria for ceftaroline. Ceftaroline was less active than ceftaroline-avibactam against all species of Enterobacteriaceae tested with rates of susceptibility ranging from 93.9% (P. mirabilis) to 54.0% (S. marcescens). All isolates of methicillin-susceptible Staphylococcus aureus (MIC<SUB>90</SUB>, 0.25 μg/ml) and 99.6% of methicillin-resistant S. aureus (MIC<SUB>90</SUB>, 1 μg/ml) were susceptible to ceftaroline; the addition of avibactam to ceftaroline did not alter its activity against staphylococci or streptococci. All isolates of Streptococcus pneumoniae (MIC<SUB>90</SUB>, 0.03 μg/ml), Streptococcus pyogenes (MIC<SUB>90</SUB>, ≤0.03 μg/ml), and Streptococcus agalactiae (MIC<SUB>90</SUB>, 0.015 μg/ml) tested were susceptible to ceftaroline. We conclude that combining avibactam with ceftaroline expanded its spectrum of activity to include most isolates of Enterobacteriaceae resistant to third-generation cephalosporins, including extended-spectrum β-lactamase (ESBL)- and AmpC-producing E. coli and ESBL-producing K. pneumoniae, while maintaining potent activity against staphylococci and streptococci.
FOOTNOTES
* Corresponding author. Mailing address: Department of Clinical Microbiology, St. Boniface Hospital, 409 Tach? Avenue, L4025-9, Winnipeg, Manitoba, R2H 2A6, Canada, Phone: (204) 237-2125. Fax: (204) 237-7678. E-mail: jkarlowsky@dsmanitoba.ca.
Copyright ? 2013, American Society for Microbiology. All Rights Reserved.
-
-------